Health and Healthcare
Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)
Published:
We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:
STOCK (Ticker) Shares Short Change
Amgen (AMGN) 29,112,550 +10.89%
Biogen Idec (BIIB) 6,648,180 (9.58%)
Celgene (CELG) 25,751,400 +12.19%
Genzyme (GENZ) 6,536,150 +12.36%
Gilead (GILD) 25,557,168 (1.59%)
Imclone (IMCL) 4,252,342 (13.49%)
Medarex (MEDX) 30,181,760 (7.72%)
As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.
Jon C. Ogg
December 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
